COYA
Coya Therapeutics Inc

1,129
Mkt Cap
$103.79M
Volume
82,020.00
52W High
$8.29
52W Low
$3.94
PE Ratio
-4.50
COYA Fundamentals
Price
$4.96
Prev Close
$4.98
Open
$4.92
50D MA
$4.96
Beta
0.94
Avg. Volume
337,125.65
EPS (Annual)
-$0.9765
P/B
3.04
Rev/Employee
$444,257.63
$48.98
Loading...
Loading...
News
all
press releases
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Recommendation of "Moderate Buy" by Brokerages
Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?
Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·4d ago
News Placeholder
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital
D. Boral Capital restated a "buy" rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Wednesday...
MarketBeat·11d ago
News Placeholder
Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar
Speakers on a Coya Therapeutics (NASDAQ:COYA) webinar outlined the company's scientific rationale and clinical development plans for an investigational combination immunotherapy in amyotrophic...
MarketBeat·12d ago
News Placeholder
Coya Therapeutics Announces $11.1 Million Private Placement
Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·1mo ago
News Placeholder
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)
D. Boral Capital reissued a "buy" rating and set a $15.00 price objective on shares of Coya Therapeutics in a report on Wednesday...
MarketBeat·1mo ago
News Placeholder
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to...
Business Wire·1mo ago
News Placeholder
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire·2mo ago
News Placeholder
D. Boral Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA)
D. Boral Capital reissued a "buy" rating and issued a $15.00 price target on shares of Coya Therapeutics in a research report on Monday...
MarketBeat·2mo ago
News Placeholder
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)
D. Boral Capital restated a "buy" rating and set a $15.00 price objective on shares of Coya Therapeutics in a research report on Tuesday...
MarketBeat·2mo ago
<
1
2
...
>

Latest COYA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.